Her-2/neu Status in Syrian Women with Breast Carcinoma: A Syrian Cohort Study of more than 10000 Cases

Maher Salamoon1*, Lina Assad2, Fariz Ahmad3, Mazen Kenj4 and Marroan Bachour1

1Department of Medical oncology, Al Bairouni University Cancer Center, Damascus, Syria
2Department of Pathology, Al Mujtahed Hospital, Damascus, Syria
3Department of Pathology, Al Bairouni University Cancer Center, Damascus, Syria
4Al Assad University Hospital, Damascus, Syria

Abstract

Background: Her-2/neu is a member of epidermal growth factor receptors (EGFR) implicated in the pathogenesis of breast cancer. Her-2/neu is known to be overexpressed in 30% of breast cancers.

Objective: the study is aimed at determining the prevalence of Her-2/neu overexpression in Syrian women diagnosed with breast cancer.

Material and Methods: The study included 10355 Syrian women diagnosed with breast cancer (invasive carcinoma NOS) during the period between 2007 and 2012 at Al Bairouni university hospital in Damascus (SYRIA). Both Her-2 (++ and ++++) were checked by FISH, [Hercep test (DAKO Inc)] to determine Her-2/neu gene status.

Results and Discussion: 2013 patients were found to be Her-2 positive (+++) forming 19.4% of the studied group, 2000 (19.3%) were (++) equivocal. On the other hand, 62% of patients were Her-2 negative (0 and 1+) scores. A further investigation of the positive and equivocal groups was performed by FISH showing positive results as follows: 1815/2013 of the (3+ patients) and 1143/2000 of the (2+ patients) respectively. In other word 57% of the (++) group were found to be FISH positive versus 9% negative FISH results in the (+++) group.

Conclusions: The prevalence of Her-2/neu in Syrian women having breast cancer in this study is 28.5%. The study reflects the distribution of real Her-2/neu gene expression among the Syrian women since Her-2 amplification was detected by FISH in both ++ and ++++ groups.

Keywords: Her-2/neu, Breast Carcinoma, Cohort Study, EGFR.

Introduction

HER-2 is an oncogene that is overexpressed and/or amplified in about one-third of breast cancer cases [1-2]. It is associated with tumor aggressiveness such as high tumor grade, lymph node metastasis, and brain metastasis [3-7]. More importantly, HER-2 is a biomarker for targeted immunotherapy such as with Trastuzumab [8-10]. Therefore, the proper evaluation of HER-2 gene status is important for breast cancer therapy. Trastuzumab therapy improves the survival rate among women with metastatic or localized HER-2- positive breast cancer [11-12]. There are 2 tests commonly used to determine HER2 status: immunohistochemistry (detects overexpression of HER2 protein)
and fluorescence in situ hybridization (detects amplification of the HER2 gene). A widely recommended testing algorithm is to consider an immunohistochemistry score of 3+ as positive, a score of 0 or 1+ as negative, and a score of 2+ as ambiguous and requiring confirmation with fluorescence in situ hybridization (FISH) [13]. Trastuzumab therapy was approved for use in women with either an immunohistochemistry score of 3+ or a positive fluorescence in situ hybridization (FISH) [13]. Trastuzumab therapy was approved for use in women with either an immunohistochemistry score of 3+ or a positive fluorescence in situ hybridization result. Studies that showed fluorescence in situ.

Hybridization to be more sensitive than immunohistochemistry in determining HER2 status [14-15] and a retrospective analysis that showed Trastuzumab therapy to be beneficial only in patients who receive a positive result of fluorescence in situ hybridization have raised the issue of whether fluorescence in situ hybridization should be used to determine the HER2 status of all women with breast cancer. In some countries (e.g., Belgium), only patients with a positive result of fluorescence in situ hybridization receive Trastuzumab therapy [16]. Immunohistochemistry is simple and could be performed in most pathology laboratories. FISH, on the other hand, is only performed in selected laboratories with suitable equipment making the test more reliable and widely considered as the test of choice in Her-2/neu gene status [17].

Box 1. illustrates the criteria used in interpretation of results for both immunohistochemistry and FISH

| Immunohistochemistry | Fluorescence in situ hybridization |
|----------------------|-----------------------------------|
| • Monoclonal antibodies recognize and bind to HER2 protein in the tissue section, which allows the tester to visualize the location and relative amount of HER2 protein | Result is positive for HER2 amplification if the ratio of HER2 signals to chromosome 17 centromeres is greater than 2.2 |
| • Scoring system | |
| 0: no circumferential membrane staining (negative) | |
| 1+: partial staining in more than 10% of cells (negative) | |
| 2+: thin circumferential staining in more than 10% of cells (ambiguous) | |
| 3+ intense circumferential membrane staining (positive) | |

Box 1. Criteria used for interpretation of results for both immunohistochemistry and fluorescence in situ hybridization.

Materials and Methods

Patients

Only patients with invasive carcinoma (NOS) were included in the study. 11013 breast cancer cases with different histologies, among which 10355 cases of primary invasive breast cancer diagnosed between January 2007 and December 2012 at Al Bairouni university hospital in Damascus (SYRIA). 658 patients presented with different histologies including: fibroadenomas, medullary carcinoma, intraductal carcinoma, myeloid sarcomas, Non-Hodgkin Lymphoma and phylloid tumors. Those 658 patients were excluded from the study because of the lack of Her-2 expression. Al Bairouni university hospital is the central cancer center in Syria where almost all cancer registries are recorded. We retrospectively reviewed reports and image files from FISH studies for the HER-2 genes. Clinicopathologic parameters such as age at initial diagnosis, histologic type, and histologic grade, stage of disease, estrogen receptor status, progesterone receptor status, and HER-2 IHC results were obtained from pathology reports. The histological grade was assessed using the Nottingham grading system [18]. HER-2 staining was analyzed according to the American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines as mentioned in Box (1).

FISH Analysis

Before FISH analysis, invasive tumors were examined on hematoxylin–eosin stained slides. FISH was subsequently performed on the tested tumor. FISH was performed using a PathVysion HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, USA) according to the manufacturer’s instructions. HER-2 gene copy number on the slides was evaluated using an epifluorescence microscope (Olympus, Tokyo, Japan). At least 100 tumor cell nuclei in three separate regions were investigated for HER-2 and chromosome 17 signals. An absolute HER-2 gene copy number lower than 4 or a HER-2/chromosome 17 copy ratio (HER-2/Chr 17) less than 1.8 was considered HER-2 negative. An absolute HER-2 copy number between 4 and 6 or a HER-2/Chr 17 ratio between 1.8 and 2.2 was considered HER-2 equivocal. An absolute HER-2 copy number greater than 6 or a HER-2/Chr 17 ratio higher than 2.2 was considered HER-2 positive [19]. Chromosome 17 polysomy was defined as a centromeric chromosome 17 spot count of 3.0 or more in at least 80% of tumor cells [20]. High-grade amplification was defined as a HER-2/Chr 17 ratio higher than 5.0, and low-grade amplification was defined as a HER-2/Chr 17 ratio greater than 2.2 but less than 5.0 [21, 22]. HER-2 gene heterogeneity (GH) was defined as more than 5% but less than 50% of the analyzed invasive tumor cells having a HER-2/Chr 17 ratio higher than 2.2, according to CAP guidelines [23].

Statistical Analysis

Data were processed using SPSS for Windows, version 12.0 (SPSS Inc., Chicago, IL, USA).

Results

Patient Characteristics

With a mean age of 42 years old at diagnosis, 2013 patients were found to be Her-2 positive (+ + +) forming 19.4% of the studied group, 2000 (19.3%) were (+ +) equivocal. On the other hand, 62% of patients were Her-2 negative (0 and 1+) scores. A further investigation of the positive and equivocal groups was performed by FISH showing positive results as follows: 1815/2013 of the (3+ patients) and 1143/2000 of the (2+ patients) respectively. In other words 57% of the (+ +) group were found to be FISH positive versus 9% negative FISH results in the (+ + +) group. Detailed information about patient characteristics is illustrated in table (1).
Of the 1958 cases with positive FISH results, Her-2 gene heterogeneity (GH) was observed in 233 (11.8%) cases, all of which were Invasive Ductal Carcinoma (IDC) with higher proportion of borderline Her-2 gene amplification status than other IDC without heterogeneity (P < 0.002). The incidence of chromosome 17 polysomy was higher in patients with Her-2 GH group than cases without (P < 0.0001). Her-2 amplification associated with intermediate grade (Grade II) in about 50% of cases and accompanied with high tendency of node metastasis.

Table 1. Patients characteristics (IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, ER: estrogen receptors, PR: progesterone receptors)

| Characteristics | Total N= 10355 (%) | Her-2 positive N= 2822 (27%) | Her-2 negative N= 7533 (63%) | P value |
|-----------------|-------------------|------------------------------|-----------------------------|---------|
| Median age      | 42 years          | 39                           | 45                          |         |
| Histologic type | IDC               | 9563 (92%)                   | 2802 (92%)                  | 0.009   |
|                 | ILC               | 792 (8%)                     | 20 (2.5%)                   |         |
| Metastasis to lymph Nodes |         |                              |                             |         |
| Liver           | 8713 (84%)        | 1917 (68%)                   | 5113 (67.8%)                |         |
| Lung bone       | 814               | 399 (49%)                    | 415 (51%)                   |         |
|                 | 723               | 294 (40%)                    | 429 (60%)                   |         |
|                 | 1453              | 512 (35%)                    | 941 (65%)                   |         |
| Stage           | I                 | 244/10355 (2.3%)             | 86 (3.04%)                  |         |
|                 | II                | 2113/10355 (20%)             | 677 (31%)                   |         |
|                 | III               | 4810/10355 (46%)             | 1310 (46.4%)                |         |
|                 | IV                | 3168/10355 (30.7%)           | 549 (19.4%)                 |         |
| Grade III       | 7010              | 3134 (44%)                   | 3876 (52%)                  | 0.0002  |
| Positive ER     | 6910              | 2310 (33%)                   | 4600 (67%)                  |         |
| Positive PR     | 5814              | 1988 (34%)                   | 3826 (66%)                  |         |

Only 244 patients (2.3%) presented with stage I disease, 2113 patients (20%) presented with stage II disease, 4810 (46%) presented with stage III while the remaining 3188 (30.7%) presented with stage IV disease.

Discussion

Over expression of HER2/neu has been shown to be associated with bad prognosis in patients with node-positive breast cancer and possibly with a node negative breast cancer.

Determination of HER2/neu status appears to be of prognostic and predictive value for patient and physician, and can be readily performed in most hospitals as part of routine clinical assessment for breast cancer patients. There is evidence that women in whom tumor over express HER2/neu are likely to get greater benefit from therapy with anthracycline-containing regimens than from alkylating agents. It is therefore, reasonable to assess HER2/neu on all primary breast tumors at the time of diagnosis [28].

The availability of an efficacious, yet expensive, treatment for HER2-positive breast cancer underlines the need for accurate determination of HER2 status. Our study concluded more than 10000 patients with breast invasive carcinoma showing Her-2/ neu gene amplification in 2958/10355 (28.5%) of cases which reflects the accurate percentage because even 3+ cases were evaluated as well as cases with equivocal results by FISH. In the course of study, we noticed that the (++) status of Her-2 expression by immunohistochemistry was seen to be negative in 9% of cases. The former result is very important from both clinical and economic point of view, because Trastuzumab is given to all patient in that group (+++ status) according to treatment guidelines and irrespective of Her-2 gene status by FISH, the thing that enable us to give the medication in the proper indication and save money as well.

Breast cancer GH results from clonal diversification and differences in genetic composition from growing genetic instability in some part of the tumor [24, 25]. In our study, Her-2/neu GH was observed in 8.25% of all studied cases with positive Her-2. Genetic differences in a single tumor were shown by laser microdissection and a comparative genomic hybridization study, and these differences were confirmed by FISH and microsatellite instability analysis [26]. HER-2 GH could be explained by acquisition or loss of the HER-2 gene, but HER-2 gene amplification is more plausible, considering that HER-2 is associated with tumor aggressiveness [27]. Therefore, Her-2/neu GH needs careful study and interpretation of FISH because signals are not homogenous on all areas of the slide.

Another issue encountered in the study is the case of chromosome 17 polysomy which was observed in 86 out of 2958 (2.9%) of Her-2 positive cases, an example is illustrated in image (G). In this case, we do not know exactly when and where to give Trastuzumab, however Trastuzumab was not offered for those patients according to our own guidelines. In some cases we noticed both Her-2 positive and negative trisomy, also Her-2 positive pentasomy and hexasomy were seen in some patients as well (as seen in images H and F respectively). Her-2 positive and negative trisomy was also observed (5 cases positive and 21 negative as illustrated in images (E) and (B) respectively.

(A) Her-2 negative

(B) Her-2 trisomy negative
In this study, we reported about 300 cases with Her-2 GH and to avoid interpretation bias, we followed ASCO guidelines by scanning the entire slide (scanning more than 4 fields) [27]. Finally, the incidence of Her-2 in Syria seems to be similar to the international prevalence (20-30%), however, documented positive cases were confirmed by FISH, making our results more trustable. Therefore, Trastuzumab is not indicated in Syria unless Her-2 is positive in both ++ and +++ status.

Acknowledgement

We thank Al Bairouni cancer center for support and Kenj cytogenetic lab for technical support and review of some cases.

Conflict of Interest

Authors state no conflict of interest.

References

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177-182.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905): 707-712.
3. Borg A, Baldeotev B, Fernö M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 1991; 6(1): 137-143.
4. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991; 49(5): 650-655.
5. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991; 63(3): 439-443.
6. McCann AH, Dervan PA, O’Regan M, Codd MB, Gullick WJ, Tobin BM, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991; 51(12): 3296-3303.
7. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Ambazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992; 10(7): 1049-1056. doi: 10.1200/JCO.1992.10.7.1049
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783-792. doi: 10.1056/NEJM200103153441101
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16): 1659-1672. doi: 10.1056/NEJMoa052306
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684. doi: 10.1056/NEJMoa052122
11. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer: a rare event. Breast J. 2007; 13(2): 122-129. doi: 10.1111/j.1524-4741.2007.00396.x
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792. doi: 10.1056/NEJM20010315344101
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol.* 1999; 17(9): 2639-2648. doi: 10.1200/JCO.1999.17.9.2639

14. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. *JAMA.* 2004; 291(16): 1972-1977. doi: 10.1001/jama.291.16.1972

15. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. *J Pathol.* 2001; 195(4): 422-428. doi: 10.1002/path.971

16. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol.* 2002; 20(14): 3095-3105. doi: 10.1200/JCO.2002.09.094

17. Neyt MJ, Albrecht JA, Clarysse B, et al. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. *Int J Technol Assess Health Care.* 2005; 21(1): 132-137.

18. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: Which test to use? *J Pathol.* 2003; 199(4): 411-417. doi: 10.1002/path.1354

19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology.* 1991; 19(5): 403-410.

20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med.* 2007; 131(1): 18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2

21. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer: a rare event. *Breast J.* 2007; 13(2): 122-129. doi: 10.1111/j.1524-4741.2007.00396.x

22. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. *Am J Clin Pathol.* 1999; 112(1): 53-67.

23. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. *Am J Pathol.* 2000; 157(5): 1467-1472. doi: 10.1016/S0002-9440(10)64785-2

24. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. *Arch Pathol Lab Med.* 2009; 133(4): 611-612. doi: 10.1043/1543-2165-133.4.611

25. Nowell PC. The clonal evolution of tumor cell populations. *Science.* 1976; 194(4260): 23-28.

26. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. *Cancer Res.* 2000; 60(14): 3884-3892.

27. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P, et al. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. *Cancer Genet Cytogenet.* 1999; 110(2): 94-102.

28. Paik S, Bryant J, Tan-Chiu E, Yother G, Park C, Wickenham DL. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. *J Natl Cancer Inst.* 2000; 92(24): 1991-1998.